ACE and COVID-19: ACE mediates the breakdown of bradykinin to its inactive peptides [130] (Figure 4) and increased aldosterone-induced ACE expression in COVID-19 (Figure 3) may inactivate bradykinin, consequently preventing bradykinin-mediated increase in tPA [130,131].